Table 3.
Multivariate Cox regression of PFS.
| Median PFS | HR | 95% CI | P-value | ||
|---|---|---|---|---|---|
| Sex | Male | 8.6 months | Reference | ||
| Female | 7.5 months | 1.203 | 0.718–2.015 | 0.483 | |
| Age | <60 | 11.8 months | Reference | ||
| ≥60 | 8.1 months | 1.252 | 0.726–2.161 | 0.419 | |
| Histology | Non-squamous | 7.5 months | Reference | ||
| Squamous | 11.7 months | 0.793 | 0.483–1.303 | 0.360 | |
| Line of therapy | First line | 10.5 months | Reference | ||
| Second line | 7 months | 0.938 | 0.558–1.576 | 0.810 | |
| Third line and beyond | 5.9 months | 1.380 | 0.603–3.157 | 0.446 | |
| ECOG PS | 0 | 11.5 months | Reference | ||
| 1 | 7.5 months | 1.219 | 0.775–1.918 | 0.392 | |
| 2–4 | 5.5 months | 1.131 | 0.510–2.508 | 0.762 | |
| B cell | Low | 6.2 months | Reference | ||
| High | 11.2 months | 1.035 | 0.642–1.668 | 0.887 | |
| CD4+CD45RA− T | Low | 5.9 months | Reference | ||
| High | 11.8 months | 0.644 | 0.417–0.994 | 0.047 | |
| CD8+ T/lymphocyte (%) | Low | 11.8 months | Reference | ||
| High | 6.3 months | 1.806 | 1.122–2.905 | 0.015 | |